Cerecor, a clinical-stage biopharmaceutical company developing treatments for neurological and psychiatric disorders, has appointed Steven Boyd and Peter Greenleaf to its Board of Directors.
Steven J. Boyd
Steven Boyd is the Chief Investment Officer of Armistice Capital. He founded Armistice in 2012, which was named Best New Hedge Fund by Hedge Funds Review the following year.
Prior to Armistice, Boyd was an analyst at Senator Investment Group and York Capital. He started his career at McKinsey and Company.
Peter Greenleaf currently serves as Chief Executive Officer and is a member of the board of directors of Sucampo Pharmaceuticals.
Prior to joining Sucampo, Greenleaf served as Chief Executive Officer and a member of the Board for Histogenics Corporation, a regenerative medicine company.
Before joining Histogenics, Greenleaf was employed by MedImmune, the global biologics arm of AstraZeneca, where he most recently served as President.
Greenleaf also served as President of MedImmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group.
He is a member of the Board of Directors of the Biotechnology Industry Organization (BIO), where he serves on the Governing Boards of the Emerging Companies and Health Sections.